학술논문
Association of blood group O with a recurrent risk for acute lower gastrointestinal bleeding from a multicenter cohort study
Document Type
article
Author
Sho Suzuki; Naoyuki Tominaga; Tomonori Aoki; Eiji Sadashima; Tadashi Miike; Hiroshi Kawakami; Katsumasa Kobayashi; Atsushi Yamauchi; Atsuo Yamada; Jun Omori; Takashi Ikeya; Taiki Aoyama; Yoshinori Sato; Takaaki Kishino; Naoki Ishii; Tsunaki Sawada; Masaki Murata; Akinari Takao; Kazuhiro Mizukami; Ken Kinjo; Shunji Fujimori; Takahiro Uotani; Minoru Fujita; Hiroki Sato; Toshiaki Narasaka; Junnosuke Hayasaka; Tomohiro Funabiki; Yuzuru Kinjo; Akira Mizuki; Shu Kiyotoki; Tatsuya Mikami; Ryosuke Gushima; Hiroyuki Fujii; Yuta Fuyuno; Takuto Hikichi; Yosuke Toya; Kazuyuki Narimatsu; Noriaki Manabe; Koji Nagaike; Tetsu Kinjo; Yorinobu Sumida; Sadahiro Funakoshi; Kiyonori Kobayashi; Tamotsu Matsuhashi; Yuga Komaki; Mitsuru Kaise; Naoyoshi Nagata
Source
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Subject
Language
English
ISSN
2045-2322
Abstract
Abstract The relationship between blood group and rebleeding in acute lower gastrointestinal bleeding (ALGIB) remains unclear. This study aimed to investigate the association between blood group O and clinical outcomes in patients with ALGIB. The study included 2336 patients with ALGIB whose bleeding source was identified during initial endoscopy (from the CODE BLUE-J Study). The assessed outcomes encompassed rebleeding and other clinical parameters. The rebleeding rates within 30 days in patients with blood group O and those without blood group O were 17.9% and 14.9%, respectively. Similarly, the rates within 1 year were 21.9% for patients with blood group O and 18.2% for those without blood group O. In a multivariate analysis using age, sex, vital signs at presentation, blood test findings, comorbidities, antithrombotic medication, active bleeding, and type of endoscopic treatment as covariates, patients with blood group O exhibited significantly higher risks for rebleeding within 30 days (odds ratio [OR] 1.31; 95% confidence interval [CI] 1.04–1.65; P = 0.024) and 1 year (OR 1.29; 95% CI 1.04–1.61; P = 0.020) compared to those without blood group O. However, the thrombosis and mortality rates did not differ significantly between blood group O and non-O patients. In patients with ALGIB, blood group O has been identified as an independent risk factor for both short- and long-term rebleeding.